Friday, 15 Dec 2017

You are here

The RheumNow Week in Review – 24 February 2017

Dr. Jack Cush reviews highlights from the past week on

  1. Study of >43K Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis patients show a 14-34% increase risk for depression; but not for suicide or suicidal ideation.
  2. Scleroderma Renal Crisis Criteria include HTN, Acute Kidney Injury, encephalopathy, seizures, microangiopathic hemolytic anemia
  3. 183 SLE Patients in a Phase II trial showed no benefit with IL-6 inhibition(PF-04236921) for 6 mos. The highest dose was D/C for safety.
  4. #RWCS17 Dr Bergman shows incredibly poor adherence to drug therapy. Suggests you need time and a plan to combat
  5. Analysis 26 studies failed to show any predictors of mycohenolate mofetil responses in Lupus. More research needed.
  6. Metanalysis shows no Cancer risk with Inflx (OR 1.68), ETN (0.79), ADA (0.93), ABA (1.04), RTX (0.58), TCZ (0.60), Tofa (1.15)
  7. Prior Authorizations is a problem for GI docs too - 63% use >25% FTE to do PA and 73% make > 5 calls (37% >10 calls) per day to payors
  8. CDC reports seasonal Influenza peaked in 2nd week Feb 2017 & will continue for weeks. No antiviral resistance seen thus far.
  9. Dr Mahadevan #RWCS17 shows data that there is a 1/2000 risk of bone fractures with chronic PPI use
  10. Dr Mahadevan #RWCS17 shows that PPI chronic use yields a 1/4000 risk of PPI induced C. ridicule diarrhea
  11. #rwcs2017 Dr Kavanaugh shows RCT where apemilast does well against etanercept in psoriasis.
  12. Dr Kevin Winthrop at #RWCS2017 reviews DMARD/Biologic effects on vaccine responses. Most effected by RTX, least by MTX.
  13. ORAL strategy trial shows Xeljanz +MTX = Humira +MTX; but was inferior as monoRx Xeljanz in 1152 RA pts over 12 mos
  14. FDA approves the IL-17 inhibitor “Siliq” (brodalumab; from Valeant) for moderate-severe plaque psoriasis.Comes with a black box warning for suicide.
  15. Baricitinib (trade name “Olumiant” ) approved by EMA for use in EU for moderate-to-severe RA as monotherapy or combo with MTX.
  16. Higher Hip and Knee Replacement Revision Rates in Younger Patients 
  17. Sirukumab shows moderate efficacy in Rheumatoid Arthritis
  18. Abatacept shows modest efficacy in Giant Cell Arteritis
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

The RheumNow Week in Review - 8 December 2017

Dr. Jack Cush covers the news and journal articles published on RheumNow.comin the past week.

Rheumatology Year in Review

During 2017, the improvements and refinements seen during previous years in the treatment of rheumatoid arthritis have been extending to other conditions ranging from psoriatic arthritis to lupus and for both monoclonal antibodies and oral small molecule medications.

Advances for Biologics

The ACR17 RheumNow Week in Review - 1 December 2017

Dr Jack Cush reviews nighlights and news from the past 2 weeks on This week's report includes new drug approvals, disappointing ACR guidelines, Lyme & Zika, infertility, dermatomyositis skin outcomes and myositis-associated cancer testing.

ACR Clinical Guidelines Flawed by Low Evidence

JAMA Internal Medicine has reported that recommendations and clinical practice guidelines from the American College of Rheumatology are often based on expert opinion, but lack rigorous (grade A) evidence to support many of their recommendations. 

RheumNow ACR 2017 Awards

The Annual Meeting of the American College of Rheumatology is a gargantuan educational and professional event that is on nearly everyone's radar each year. RheumNow had an expansive effort to cover this meeting and you can review the work of our faculty at  But we have decided to take this one step further and today we are announcing our 2017 RheumNow ACR Awards.